• Advances in Traditional Medicine
• /
• 제1권1호
• /
• pp.45-54
• /
• 2000

Cannabidiol derivatives (1, 2 and 3), and 5-fluorouracil (4, 5-FU) were tested for their growth inhibitory effects against human oral epitheloid carcinoma cell lines (KB) using two different 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay and sulforhodamine B protein (SRB) assay. These compounds showed a potent inhibitory activity in vitro in the micromolar range against KB cell lines. In general, the antitumor activity of these compounds (1, 2, 3 and 4) was in a dose-dependent over the micromolar concentration ranges from $1\;{\mu}M\;to\;100\;{\mu}M$. The comparison of $IC_{50}$ values of these compounds in tumor cell lines shows that their susceptibility to these compounds decreases in the following order: CBD > 5-FU > CBDME > CBDDE by the MTT assay and SRB assay. Cannabidiol derivatives (1, 2 and 3), and 5-FU were tested for their cytotoxic effects on NIH 3T3 fibroblasts using two different MTT assay and SRB assay. These compounds exhibited potent cytotoxic activities in vitro in the micromolar range against NIH 3T3 fibroblasts. In general, the cytotoxic activities of these compounds (1, 2, 3 and 4) were in a dose-dependent over the micromolar concentration range $1\;{\mu}M\;to\;100\;{\mu}M$. The comparison of $CD_{50}$ values of these compounds on NIH 3T3 fibroblasts shows that their susceptibility to these compounds decreases in the following order; CBD > 5-FU > CBDDE > CBDME by MTT assay, CBD > 5-FU > CBDME > CBDDE by SRB assay. These results suggest that cannabidiol (1, CBD) retains the most growth-inhibitory activity against KB cell lines.

• Biomolecules & Therapeutics
• /
• 제16권2호
• /
• pp.87-94
• /
• 2008

In view of obtaining potential anticancer compounds, we studied the inhibitory activity and the cytotoxic effects of a candidate compound in cancer cells. The cytotoxic effects of cannabidiol (CBD) in vitro were evaluated in NIH3T3 fibroblasts, B16 melanoma cells, A549 lung cancer cells, MDA-MB-231 breast cancer cells, Lenca kidney cells and SNU-C4 colon cancer cells. The cells were cultured in various concentrations of CBD for 48 h and 25 ${\mu}$M of CBD for 6-36 h. The cells were observed to exhibit inhibitory effects of the cell viability in their growth, and then cytotoxicity was estimated. The inhibitory activity of CBD was increased in all cancer cells and showed especially strong increment in breast cancer cells. The cytotoxicity of CBD increased in a dose- and time-dependent manner with growth inhibition in all cancer cell lines. Also, to assess the membrane toxicity induced by CBD, we investigated lactate dehydrogenase (LDH) release. After treatment with various concentrations of CBD, LDH release rate of cancer cells was accelerated. On the other hand, in the induction of cell death, caspase-3, -8 and -9 activations were detected in cancer cells after treatment with various concentrations of CBD, and CBD effectively induced activity of caspase-3, -8 and -9 in A549 lung cancer cells, MDAMB-231 breast cancer cells and Renca kidney cells. Therefore these results suggest that CBD has a possibility of anticancer agents and anticancer effects against cancer cells by modulation of apoptotic pathway in the range of 5-80 ${\mu}$M concentration.

• 대한화장품학회지
• /
• 제48권4호
• /
• pp.313-319
• /
• 2022

본 연구에서는 국내산 대마로부터 추출된 순도 99% 이상 칸나비디올(cannabidiol, CBD)을 1% 함유한 크림의 안정성을 평가하였다. 12 주간 온도별 저장조건(4 ℃, 25 ℃, 37 ℃, 45 ℃)에서 2 주 간격으로 pH, 경도, 함량, 색도를 측정하였다. CBD를 1% 함유한 실험군 의 pH는 대조군보다 더 감소하는 경향을 나타내었다. HPLC를 이용하여 온도별로 12 주 동안 실험군 내 CBD의 함량 변화를 확인한 결과, 온도에 따른 감소량의 차이를 확인하였다. 분광측색계를 이용하여 색차를 확인한 결과, 저장 기간 및 온도 증가에 따라 대조군에 비해 실험군 황색도가 증가함을 확인하였다. 이상의 결과로부터 pH 5 ~ 6의 실험군 제형의 온도에 따른 함량 감소 및 색상 변화를 확인하였다. CBD를 향후 의약품 및 화장품에 적용 시 온도에 따른 CBD의 역가 및 이화학적 품질변화를 고려한 연구개발이 수행되어야 할 것으로 판단된다.

• 생명과학회지
• /
• 제33권4호
• /
• pp.343-348
• /
• 2023

여드름은 가장 흔한 피부 질환 중 하나로 청소년기에 주로 발생한다. 호르몬, 유전, 환경적 요인이 알려져 있으며, 이 외에도 피부 과각화 및 C. acnes의 과증식 등이 여드름 발병에 중요한 역할을 한다. CBD는 통증과 스트레스 완화 및 항염증 특성을 갖는 것으로 알려져 있다. 뿐만 아니라, CBD가 함유된 대마 추출물이 여드름 완화 및 치료에 효과적인 소재로 보고되었다. 그러나 이에 대한 연구는 부족한 실정으로, 본 연구를 통하여 피지세포에서 CBD의 항여드름 활성을 확인하고자 하였다. 본 연구진은 세포에 CBD를 처리하여 지질 합성과 증식에 대한 억제 효과를 확인할 수 있었다. 그런 다음 CBD가 SREBP-1를 통해 지방 생성에 대한 억제 효과를 가지는 것을 입증했다. 또한 SREBP-1의 상위 조절자인 Akt와 AMPK가 CBD에 의해 조절되는 것을 확인했다. 종합하면, 본 연구 결과를 통해 CBD가 Akt/AMPK-SREBP-1 경로 조절을 통해 지방 생성을 억제하여 여드름 완화 소재로 이용될 수 있음을 시사하였다. 과각화증으로 인한 염증에 대한 CBD의 효과를 확인하기 위한 추가 연구가 필요하며, 이는 여드름에 대한 CBD의 활용 가능성을 높일 수 있을 것으로 사료된다.

• 생명과학회지
• /
• 제33권3호
• /
• pp.234-241
• /
• 2023

최근 세계 여러 나라에서 대마초 및 대마제품을 합법화하고 대마를 이용한 다양한 치료법에 대한 연구가 활발히 진행되고 있다. 그러나 대마에는 생물학적 효과가 아직 확립되지 않은 여러 화합물들이 포함되어 있다. 본 연구에서는 인간 모유두 세포(HDPC)의 모발 성장에 대한 칸나비디올(CBD)의 효과를 조사하였다. 2,2'-Azino-bis (3-ethylbenzothiazolin-6-sulfonic acid) (ABTS) 및 2,2-diphenyl-1-picrylhydrazyl (DPPH) 라디칼 소거 분석법을 활용하여 CBD의 항산화 활성을 측정하였다. 모유두 세포에서 CBD의 세포생존률은 WST-1 분석법으로 측정하였다. CBD 처리에 의한 모유두 세포에서 모발 성장과 관련된 인자의 발현은 real-time PCR 및 western blot으로 측정하였다. CBD의 항산화 활성 측정결과, DPPH 및 ABTS 자유 라디칼 소거 활성의 IC50 값은 각각 15.46±0.24 μM 및 13.90±0.06 μM으로 뛰어난 활성 산소 제거능을 나타냈다. CBD 처리군은 대조군에 비해 세포 증식이 증가하는 경향을 나타냈다. 또한 모유두 세포에서 Real-Time PCR과 Western blotting을 통해 모발 성장 관련 인자를 측정한 결과, CBD 처리로 인하여 성장 관련 인자들이 증가하는 것으로 나타났다. 종합적으로, 항산화 활성이 높은 CBD는 모유두 세포에서 세포 증식을 증가시키고 모발 성장 관련 인자들을 긍정적으로 조절합니다. 이러한 결과는 CBD가 탈모증에 대한 잠재적으로 활용될 수 있음을 시사한다.

• 한국자원식물학회:학술대회논문집
• /
• 한국자원식물학회 2022년도 추계학술대회
• /
• pp.121-121
• /
• 2022

마자인(麻子仁)은 뽕나무과에 속하는 대마(Cannabis sativa L.)의 종자로써, 治血虛津虧, 腸燥便秘하며, 中風汗出, 逐水, 利小便, 破積血, 復血脈, 乳婦産後餘疾, 長髮 등에 사용한다고 기록되어 있다. 마자인 종자의 외피에는 환각성분인 Tetrahydrocannabinol (THC) 및 뇌전증과 다발성경화증 등 희귀, 난치성 질환의 치료제로 사용되는 Cannabidiol (CBD) 성분이 함유되어 있다. 따라서 외피를 제거한 마자인은 햄프씨드(Hemp Seed)로써 식품으로 이용되지만, 외피를 제거하지 않은 마자인은 의약품으로써 사용이 되고 있다. 마자인은 윤조탕, 자윤환, 마자인환 등 다양한 한의학 처방에 사용되지만, 외피에 함유되어있는 THC 및 CBD의 함유량 및 안전성에 대한 연구는 밝혀지지 않았다. 이에 마자인 함유처방의 안전성을 입증하는 실험방법을 설계하였다. 우선 의약품으로 유통되는 마자인의 외피에 THC 및 CBD 성분이 있는지를 확인하기 위해 마자인을 다양한 용매별 (물, 헥산 등)로 추출한 후 LC/MS를 이용해 성분 유무를 확인한다. 또한, 마자인 함유 처방 (마자인환, 자윤환, 윤조탕 등)을 복용하였을 경우 혈중에 THC 및 CBD 성분이 있는지를 확인하는 방법으로 실험동물에 마자인 함유 /처방을 투여한 후 혈액을 채취한다. 마찬가지로 성분 유무를 측정하는 방법은 LC/MS를 이용해 확인한다.

• Toxicological Research
• /
• 제16권2호
• /
• pp.101-107
• /
• 2000

Cannabidiol derivatives (1, 2 and 3), 5-fluorouracil (4, 5-FU) and adriamycin (5, AM) were tested for their growth inhibitory effects against human tumor cell lines using two different 3-{4,5-dimeth-ylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay and sulforhodamine B protein (SRB) assay. The light microscopic study showed morphological changes of the treated cells. Disruptions in cell organelles were determined by colorimetric methods; MTT assay and STB assay. These results suggest that cannabidiol (1, CBD) retains the most growth-inhibitory activity against human tumor cell lines.

• 대한약침학회지
• /
• 제24권2호
• /
• pp.68-75
• /
• 2021

Objectives: The hair follicle is composed of more than 20 kinds of cells, and mesoderm derived dermal papilla cells and keratinocytes cooperatively contribute hair growth via Wnt/β-catenin signaling pathway. We are to investigate β-catenin expression and regulatory mechanism by CBD in alopecia hair tissues and dermal papilla cells. Methods: We performed structural and anatomical analyses on alopecia patients derived hair tissues using microscopes. Pharmacological effect of CBD was evaluated by β-catenin expression using RT-PCR and immunostaining experiment. Results: Morphological deformation and loss of cell numbers in hair shaft were observed in alopecia hair tissues. IHC experiment showed that loss of β-catenin expression was shown in inner shaft of the alopecia hair tissues, indicating that β-catenin expression is a key regulatory function during alopecia progression. Consistently, β-catenin expression was decreased in testosterone or PMA treated dermal papilla cells, suggesting that those treatments are referred as a model on molecular mechanism of alopecia using dermal papilla cells. RT-PCR and immunostaining experiments showed that β-catenin expression was decreased in RNA level, as well as decreased β-catenin protein might be resulted from ubiquitination. However, CBD treatment has no changes in gene expression including β-catenin, but the decreased β-catenin expression by testosterone or PMA was restored by CBD pretreatment, suggesting that potential regulatory effect on alopecia induction of testosterone and PMA. Conclusion: CBD might have a modulating function on alopecia caused by hormonal or excess of signaling pathway, and be a promising application for on alopecia treatment.

• Archives of Pharmacal Research
• /
• 제23권2호
• /
• pp.121-127
• /
• 2000

Cannabigerol (1, CBG), methyl 4-[(2E)-3,7-dimethyl-2,6-octad ienyl)oxy]-3-methoxybenzoate (2, DTM), 5-fluorouracil (3, FU) as a reference, and cannabidiol (4, CBD) were tested for their growth inhibitory effects against KB(ATCC NO, OCL 17) cell lines using two different assays, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazoliumbromide (MTT) assay and the sulforhod-amine B protein (SRB) assay. These compounds showed inhibitory activity in vitro in the micromolar range against KB cell lines. In general, the antitumor activities of these compounds (1, 2, 3 and 4) were dose-dependent over the micromolar concentration range of 1 to 100 M. The comparison of $IC_{50}$ values of these compounds in tumor cell lines showed that their susceptibility to these compounds decreases in the following order: DTM > CBD > 5-FU > CBG by MTT assay and DTM = CBD > 5-FU > CBG by SRB assay. CBG 1, DTM 2, 5-FU 3, and CBD 4 were tested for their cytotoxic effects on NIH 3T3 fibroblasts using two different assays, the MTT assay and SRB assay. These compounds exhibited potent cytotoxic activities in vitro in the micromolar range against NIH 3T3 fibroblasts. In general, the cytotoxic acivities of these compounds (1, 2, 3 and 4) were dose-dependent over the micromolar concentraion range of 1 to 100 M. The comparison of $CD_{50}$ values of these compounds in NIH 3T3 fibroblasts shows that their susceptibility to these compounds in decreases the following order(:) CBD > 5-FU > DTM > CBG by MTT assay, CBD > 5-FU > CBG > DTM by SRB assay. These results suggest that DTM 2 has the most growth-inhibitory activity against KB cell lines.

• Journal of Dental Anesthesia and Pain Medicine
• /
• 제21권6호
• /
• pp.479-506
• /
• 2021

Background: Chronic neuropathic pain (NP) presents therapeutic challenges. Interest in the use of cannabis-based medications has outpaced the knowledge of its efficacy and safety in treating NP. The objective of this review was to evaluate the effectiveness of cannabis-based medications in individuals with chronic NP. Methods: Randomized placebo-controlled trials using tetrahydrocannabinol (THC), cannabidiol (CBD), cannabidivarin (CBDV), or synthetic cannabinoids for NP treatment were included. The MEDLINE, Cochrane Library, EMBASE, and Web of Science databases were examined. The primary outcome was the NP intensity. The risk of bias analysis was based on the Cochrane handbook. Results: The search of databases up to 2/1/2021 yielded 379 records with 17 RCTs included (861 patients with NP). Meta-analysis showed that there was a significant reduction in pain intensity for THC/CBD by -6.624 units (P < .001), THC by -8.681 units (P < .001), and dronabinol by -6.0 units (P = .008) compared to placebo on a 0-100 scale. CBD, CBDV, and CT-3 showed no significant differences. Patients taking THC/CBD were 1.756 times more likely to achieve a 30% reduction in pain (P = .008) and 1.422 times more likely to achieve a 50% reduction (P = .37) than placebo. Patients receiving THC had a 21% higher improvement in pain intensity (P = .005) and were 1.855 times more likely to achieve a 30% reduction in pain than placebo (P < .001). Conclusion: Although THC and THC/CBD interventions provided a significant improvement in pain intensity and were more likely to provide a 30% reduction in pain, the evidence was of moderate-to-low quality. Further research is needed for CBD, dronabinol, CT-3, and CBDV.